Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocklatan as Replacement Therapy in Glaucoma and Ocular Hypertension
NCT05283395Phase 4Completed
- Sponsor
- Aerie Pharmaceuticals
- Start
- Mar 2022
- Primary completion
- Mar 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of netarsudil + latanoprost in Open-angle glaucoma (OAG), ocular hypertension, sponsored by Aerie Pharmaceuticals. Started Mar 2022; status: completed.
02
Drugs
netarsudil + latanoprost
03
Conditions
Open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT05283395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05283395.